Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

826 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Single response assessment of transplant-ineligible multiple myeloma: a supplementary analysis of JCOG1105 (JCOG1105S1).
Nakamura N, Maruyama D, Machida R, Ichinohe T, Takayama N, Ohba R, Ohmachi K, Imaizumi Y, Tokunaga M, Katsuya H, Yoshida I, Sunami K, Kurosawa M, Kubota N, Morimoto H, Kobayashi M, Kato H, Kameoka Y, Kagami Y, Kizaki M, Takeuchi K, Munakata W, Iida S, Nagai H. Nakamura N, et al. Among authors: kubota n. Jpn J Clin Oncol. 2021 Jul 1;51(7):1059-1066. doi: 10.1093/jjco/hyab066. Jpn J Clin Oncol. 2021. PMID: 33959770 Free PMC article. Clinical Trial.
Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Ohmachi K, Ando K, Ogura M, Uchida T, Itoh K, Kubota N, Ishizawa K, Yamamoto J, Watanabe T, Uike N, Choi I, Terui Y, Usuki K, Nagai H, Uoshima N, Tobinai K; Japanese Bendamustine Lymphoma Study Group. Ohmachi K, et al. Among authors: kubota n. Cancer Sci. 2010 Sep;101(9):2059-64. doi: 10.1111/j.1349-7006.2010.01635.x. Cancer Sci. 2010. PMID: 20626754 Free article. Clinical Trial.
Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial.
Watanabe T, Tobinai K, Wakabayashi M, Morishima Y, Kobayashi H, Kinoshita T, Suzuki T, Yamaguchi M, Ando K, Ogura M, Taniwaki M, Uike N, Yoshino T, Nawano S, Terauchi T, Hotta T, Nagai H, Tsukasaki K; JCOG0203 Collaborators. Watanabe T, et al. Lancet Haematol. 2018 Nov;5(11):e520-e531. doi: 10.1016/S2352-3026(18)30155-8. Lancet Haematol. 2018. PMID: 30389034 Clinical Trial.
Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin.
Yamaguchi M, Suzuki R, Miyazaki K, Amaki J, Takizawa J, Sekiguchi N, Kinoshita S, Tomita N, Wada H, Kobayashi Y, Niitsu N, Ando T, Maeda T, Saito B, Matsuoka H, Sakai R, Kubota N, Masaki Y, Kameoka Y, Asano N, Oguchi M, Katayama N. Yamaguchi M, et al. Among authors: kubota n. Ann Hematol. 2019 Jul;98(7):1647-1655. doi: 10.1007/s00277-019-03689-9. Epub 2019 Apr 19. Ann Hematol. 2019. PMID: 31001658 Clinical Trial.
Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
Yamauchi N, Maruyama D, Choi I, Atsuta Y, Sakai R, Miyashita K, Moriuchi Y, Tsujimura H, Kubota N, Yamamoto G, Igarashi T, Izutsu K, Yoshida S, Kojima K, Uchida T, Inoue Y, Tsukamoto N, Ohtsuka E, Suzuki S, Inaguma Y, Ichikawa S, Gomyo H, Ushijima Y, Nosaka K, Kurata M, Tanaka Y, Ueda R, Mizokami M, Kusumoto S. Yamauchi N, et al. Among authors: kubota n. Cancer Sci. 2021 May;112(5):1943-1954. doi: 10.1111/cas.14846. Epub 2021 Mar 18. Cancer Sci. 2021. PMID: 33576088 Free PMC article.
Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma.
Miyazaki K, Suzuki R, Oguchi M, Taguchi S, Amaki J, Maeda T, Kubota N, Maruyama D, Terui Y, Sekiguchi N, Takizawa J, Tsukamoto H, Murayama T, Ando T, Matsuoka H, Hasegawa M, Wada H, Sakai R, Kameoka Y, Tsukamoto N, Choi I, Masaki Y, Shimada K, Fukuhara N, Utsumi T, Uoshima N, Kagami Y, Asano N, Ejima Y, Katayama N, Yamaguchi M. Miyazaki K, et al. Among authors: kubota n. Hematol Oncol. 2022 Oct;40(4):667-677. doi: 10.1002/hon.2977. Epub 2022 Mar 2. Hematol Oncol. 2022. PMID: 35142384
Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105.
Suzuki T, Maruyama D, Machida R, Kataoka T, Fukushima N, Takayama N, Ohba R, Omachi K, Imaizumi Y, Tokunaga M, Katsuya H, Yoshida I, Sunami K, Kurosawa M, Kubota N, Morimoto H, Kobayashi M, Yamamoto K, Kameoka Y, Kagami Y, Tabayashi T, Maruta M, Kobayashi T, Iida S, Nagai H. Suzuki T, et al. Among authors: kubota n. Hematol Oncol. 2023 Aug;41(3):590-593. doi: 10.1002/hon.3103. Epub 2022 Nov 30. Hematol Oncol. 2023. PMID: 36416678 No abstract available.
Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203.
Watanabe T, Matsuno Y, Wakabayashi M, Maruyama D, Yamamoto K, Kubota N, Shimada K, Asagoe K, Yamaguchi M, Ando K, Ogura M, Kuroda J, Suehiro Y, Tsukasaki K, Tobinai K, Nagai H. Watanabe T, et al. Among authors: kubota n. Hematol Oncol. 2024 May;42(3):e3272. doi: 10.1002/hon.3272. Hematol Oncol. 2024. PMID: 38595316 Clinical Trial.
Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan.
Yamaguchi M, Suzuki R, Oguchi M, Asano N, Amaki J, Akiba T, Maeda T, Itasaka S, Kubota N, Saito Y, Kobayashi Y, Itami J, Ueda K, Miyazaki K, Ii N, Tomita N, Sekiguchi N, Takizawa J, Saito B, Murayama T, Ando T, Wada H, Hyo R, Ejima Y, Hasegawa M, Katayama N. Yamaguchi M, et al. Among authors: kubota n. J Clin Oncol. 2017 Jan;35(1):32-39. doi: 10.1200/JCO.2016.68.1619. Epub 2016 Oct 31. J Clin Oncol. 2017. PMID: 28034070
826 results